ProCE Banner Activity

PAOLA-1 Phase III Trial: Final Overall Survival Results of Maintenance Olaparib + Bevacizumab in Patients With Newly Diagnosed Advanced Ovarian Cancer

Slideset Download
Conference Coverage
Final OS data for the PAOLA-1 trial support the addition of olaparib to bevacizumab for patients with HRD-positive ovarian cancer receiving treatment in the frontline setting.

Released: September 27, 2022

Expiration: September 26, 2023

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp